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Authors’ responseThe potential for using topical NSAIDs or topical capsaicin
was included in a single statement in recommendation 15
simply in order to try and minimise the number of separate
statements of recommendation. No attempt was made to
amalgamate evidence relating to these very different
modalities of treatment. The best available evidence for
safety and efﬁcacy for each was assessed and discussed
separately in the published recommendations. As evidence
for efﬁcacy for both modalities was supported by a system-
atic review the Level of Evidence (LoE) for both was appro-
priately graded 1a. This does not imply that the strength or
quality of evidence for each modality of treatment is the
same. LoE must not be confused with the Strength of
Recommendation (SOR), which was based on the votes
of the guideline development group after combining consid-
eration of the best available evidence with their own expertise,*Address correspondence and reprint requests to: Dr George
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1588for the speciﬁcally worded statement relating to both modal-
ities of topical therapy contained in recommendation 15. In
the absence of RCTs with head to head comparisons no
separate recommendation was made for any individual top-
ical NSAID. RCTs and meta-analyses published after Janu-
ary 31st 2006 are currently being reviewed and will be
considered when the OARSI recommendations are updated
and revised.G. Nuki M.B. F.R.C.P.*, R. Moskowitz M.D.,
W. Zhang Ph.D.
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